Charles River Laboratories International, Inc. (NYSE:CRL) Holdings Boosted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 298,250 shares of the medical research company's stock after purchasing an additional 46,994 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.58% of Charles River Laboratories International worth $55,057,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of CRL. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after buying an additional 47,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Charles River Laboratories International by 46.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after purchasing an additional 1,679 shares during the period. Boston Trust Walden Corp boosted its position in Charles River Laboratories International by 4.3% during the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after purchasing an additional 8,338 shares during the period. E. Ohman J or Asset Management AB increased its holdings in Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after purchasing an additional 1,800 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Charles River Laboratories International by 61.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock valued at $84,000 after purchasing an additional 175 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Up 1.1%

Shares of NYSE:CRL traded up $1.46 during midday trading on Thursday, reaching $137.71. The company had a trading volume of 306,598 shares, compared to its average volume of 991,069. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market capitalization of $6.76 billion, a P/E ratio of 917.30, a PEG ratio of 4.54 and a beta of 1.50. The stock's fifty day moving average price is $130.15 and its 200-day moving average price is $161.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter in the previous year, the firm earned $2.27 EPS. The company's revenue was down 2.7% on a year-over-year basis. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CRL. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Robert W. Baird increased their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. Finally, Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and a consensus price target of $171.85.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).